Physicians' Academy for Cardiovascular Education
SGLT2 inhibition in CKD: Discussing the key questions and evidence

SGLT2 inhibition in CKD: Discussing the key questions and evidence

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.

During this educational program, the effect of SGLT2i in diabetes patients with chronic kidney disease (CKD) is disscussed in three lectures.

This course consists of the following lectures:

After watching three videos on the effect of SGLT2i in diabetes patients with chronic kidney disease (CKD), the learner should be able to:

Expert faculty

- Rajiv Agarwal, MD, MBBS, FASN is Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN, USA.

- Paola Fioretto, MD, Associate Professor in Medicine at the University of Padova, Italy

- Will Herrington, MD, Honorary Consultant Nephrologist, University of Oxford, United Kingdom

Target audience

This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating patients with diabetes and chronic kidney disease (CKD).

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim / Lilly.

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

Share this page with your colleagues and friends: